Secondary analysis of phase 3 Study 502 in 480 adults with MDD and inadequate antidepressant response: adjunctive lumateperone 42 mg improved CSFQ-14 sexual function score vs placebo at day 43 (LSMD 2.7; P<.0001). The gain in men was non-significant (P=.08).
Secondary analysisn = 480
Clayton et al. Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder